The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2013 ACR/ARHP Annual Meeting: Diagnostic,Treatment Approaches Evolve for Kawasaki Disease

2013 ACR/ARHP Annual Meeting: Diagnostic,Treatment Approaches Evolve for Kawasaki Disease

February 1, 2014 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • 2013 ACR/ARHP Annual Meeting: Better Care for Pediatric Rheumatology Patients On Horizon
  • 2015 ACR/ARHP Annual Meeting: Behçet’s Disease Poses Diagnosis, Treatment Challenges
  • 2013 ACR/ARHP Annual Meeting: Inflammatory Eye Disease Management Can Benefit from Collaboration between Rheumatologists and Ophthalmologists
Explore This Issue
February 2014
Also By This Author
  • Kristine Kuhn, MD, PhD, Takes Reins of ACR’s Committee on Research
Cool Kawasaki’s Fire
Color X-ray of a coronary artery in Kawasaki disease

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

SAN DIEGO—Kawasaki disease (KD) is not going away. These words, spoken by Jane C. Burns, MD, director of the Kawasaki Disease Research Center in the department of pediatrics at the University of California, San Diego, in La Jolla, set the context and tone for a session at the 2013 ACR/ARHP Annual Meeting, held October 26–30. [Editor’s Note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.] The session was devoted to providing rheumatologists with tools to recognize and treat KD.

Citing unpublished epidemiological data from Japan, Dr. Burns highlighted that almost 14,000 new cases of KD were diagnosed in 2012 and that one in every 85 children in Japan is predicted to develop KD during the first 10 years of life. In the United States, she said, it is estimated that one in 1,600 adults will have had KD by 2030.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

During the session, entitled “Kawasaki Disease: Putting Out the Fire,” a panel of experts provided updated information on the diagnosis and treatment of KD with an emphasis on the need for early detection to minimize complications, including the potential for the formation of coronary artery aneurysms.

Kawasaki Disease: What It Is and What It Is Not

Knowing how to recognize KD and make the differential diagnosis from other diseases is not easy, and requires familiarity with an evolving understanding of what the disease is, according to Robert Sundel, MD, program director in rheumatology at Boston Children’s Hospital, and associate professor of pediatrics at Harvard Medical School in Boston. He emphasized the limitations of the classic or traditional criteria once used to diagnose KD, and discussed more recently developed modified criteria that expanded the differential diagnosis of KD (see Table 1).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
Table 1: Criteria to Diagnose KD
click for large version
Table 1: Criteria to Diagnose KD

Among key features that led to formulation of the modified criteria was the recognition that many patients with KD have concurrent infections, complicating determination of which other conditions to consider in the differential diagnosis. Further, evolving recognition of cardiac involvement in patients who do not meet classical criteria for KD necessitated alternative approaches to optimize outcomes. Occult cardiac involvement in patients with KD includes myocarditis and, importantly, coronary artery aneurysms, he said, emphasizing that the presence of cardiac involvement is a major prognostic determinant with a mortality rate of 1.5% in untreated patients that falls to less than 0.1% in treated patients.

Pages: 1 2 3 | Single Page

Filed Under: Career Development, Education & Training, Meeting Reports, Professional Topics Tagged With: ACR/ARHP Annual Meeting, Cardiac, Diagnosis, drug, imaging, infliximab, Kawasaki disease, patient care, Pediatrics, Research, rheumatologist, TreatmentIssue: February 2014

You Might Also Like:
  • 2013 ACR/ARHP Annual Meeting: Better Care for Pediatric Rheumatology Patients On Horizon
  • 2015 ACR/ARHP Annual Meeting: Behçet’s Disease Poses Diagnosis, Treatment Challenges
  • 2013 ACR/ARHP Annual Meeting: Inflammatory Eye Disease Management Can Benefit from Collaboration between Rheumatologists and Ophthalmologists
  • 2013 ACR/ARHP Annual Meeting: Research Provides Insight into Preclinical Rheumatic Disease

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.